HER-2阳性乳腺癌的免疫治疗
Immunotherapy for HER-2 positive breast cancer.
作者信息
Yang Tingting, Kang Lihua, Li Dan, Song Yanqiu
机构信息
Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
出版信息
Front Oncol. 2023 Mar 16;13:1097983. doi: 10.3389/fonc.2023.1097983. eCollection 2023.
Abstract
Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers. As a proved effective passive immunotherapy, clinical application of the monoclonal antibodies trastuzumab, pertuzumab and T-DM1 (ado-trastuzumab emtansine) has significantly improved the survival of patients with HER2+ breast cancers. Immune checkpoint inhibitors that block programmed death receptor-1 and its ligand (PD-1/PD-L1) have also shown benefits for breast cancer in various clinical trials. Adoptive T-cell immunotherapies and tumor vaccines are emerging as novel approaches to treating breast cancer, but require further study. This article reviews recent advances in immunotherapy for HER2+ breast cancers.
摘要
免疫疗法是一种针对晚期乳腺癌的正在发展的治疗方法。免疫疗法对于三阴性乳腺癌和人表皮生长因子受体2阳性（HER2+）乳腺癌的治疗具有临床意义。作为一种已被证实有效的被动免疫疗法，单克隆抗体曲妥珠单抗、帕妥珠单抗和T-DM1（ado曲妥珠单抗）的临床应用显著提高了HER2+乳腺癌患者的生存率。在各种临床试验中，阻断程序性死亡受体1及其配体（PD-1/PD-L1）的免疫检查点抑制剂也已显示出对乳腺癌的治疗益处。过继性T细胞免疫疗法和肿瘤疫苗正在成为治疗乳腺癌的新方法，但仍需要进一步研究。本文综述了HER2+乳腺癌免疫疗法的最新进展。
相似文献
1
Immunotherapy for HER-2 positive breast cancer.HER-2阳性乳腺癌的免疫治疗
Front Oncol. 2023 Mar 16;13:1097983. doi: 10.3389/fonc.2023.1097983. eCollection 2023.
2
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.曲妥珠单抗联合阿替利珠单抗治疗早期或转移性乳腺癌对肿瘤免疫微环境的影响：来自 Ib 期研究的结果。
Clin Breast Cancer. 2021 Dec;21(6):539-551. doi: 10.1016/j.clbc.2021.04.011. Epub 2021 May 15.
3
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.提高免疫检查点抑制剂在晚期乳腺癌中疗效的新型联合策略。
Clin Transl Oncol. 2021 Oct;23(10):1979-1994. doi: 10.1007/s12094-021-02613-w. Epub 2021 Apr 19.
4
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).一项评估度伐利尤单抗联合曲妥珠单抗治疗 HER2 阳性转移性乳腺癌（CCTG IND.229）的 Ib 期临床试验。
Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16.
5
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.曲妥珠单抗-美坦新偶联物联合或不联合帕妥珠单抗对比曲妥珠单抗联合紫杉类药物用于人表皮生长因子受体 2 阳性晚期乳腺癌：来自 MARIANNE 的最终结果。
Cancer. 2019 Nov 15;125(22):3974-3984. doi: 10.1002/cncr.32392. Epub 2019 Jul 18.
6
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.帕博利珠单抗联合曲妥珠单抗恩美曲妥珠单抗治疗转移性 HER2 阳性乳腺癌的 Ib 期研究。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005119.
7
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.曲妥珠单抗-美坦新偶联物（T-DM1）联合多西他赛加或不加帕妥珠单抗治疗人表皮生长因子受体 2（HER2）阳性局部晚期或转移性乳腺癌患者的 Ib/IIa 期研究结果。
Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6.
8
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.曲妥珠单抗和帕妥珠单抗联合治疗后出现 HER2 丢失和 T-DM1 疗效降低的 HER2 阳性晚期乳腺癌：SePHER 研究。
J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.
9
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.晚期人表皮生长因子受体 2 阳性乳腺癌患者的系统治疗：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5.
10
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.ado曲妥珠单抗（ado-曲妥珠单抗）：一种HER2阳性靶向抗体药物偶联物。
Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31.
引用本文的文献
1
Causal relationships between immune cell traits and HER2 subtypes in breast cancer: a Mendelian randomization study.乳腺癌中免疫细胞特征与HER2亚型之间的因果关系：一项孟德尔随机化研究
Discov Oncol. 2025 Aug 5;16(1):1475. doi: 10.1007/s12672-025-03358-6.
2
Targeted Drug Delivery for Breast Cancer using Functionalized Liposomes: Preparation Methods, Challenges, and Clinical Translation.使用功能化脂质体的乳腺癌靶向给药：制备方法、挑战及临床转化
AAPS PharmSciTech. 2025 Aug 5;26(7):207. doi: 10.1208/s12249-025-03206-4.
3
Clinically proven natural products against breast cancer, with mechanistic insights.经临床验证的抗乳腺癌天然产物及作用机制解析
Oncol Res. 2025 Jun 26;33(7):1611-1632. doi: 10.32604/or.2025.062778. eCollection 2025.
4
Breast cancer therapy: from the perspective of glucose metabolism and glycosylation.乳腺癌治疗：从葡萄糖代谢和糖基化的角度。
Mol Biol Rep. 2024 Apr 20;51(1):546. doi: 10.1007/s11033-024-09466-w.
5
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies.乳腺癌中的免疫检查点抑制剂：进展、耐药机制及潜在管理策略
Cancer Drug Resist. 2023 Nov 17;6(4):768-787. doi: 10.20517/cdr.2023.58. eCollection 2023.
6
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.临床前和临床观察提示联合治疗可增强 Her-2/neu B 细胞肽疫苗 HER-Vaxx 的疗效并防止免疫逃逸。
Int J Mol Sci. 2023 Dec 24;25(1):287. doi: 10.3390/ijms25010287.
7
Novel HER-2 Targeted Therapies in Breast Cancer.乳腺癌中的新型HER-2靶向疗法。
Cancers (Basel). 2023 Dec 23;16(1):87. doi: 10.3390/cancers16010087.
8
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.抗体药物偶联物RC48（迪西他单抗维泊妥珠单抗）与zimberelimab（PD-1抑制剂）联合治疗成功控制了对曲妥珠单抗恩美曲妥珠单抗耐药的复发性HER2阳性乳腺癌：一例报告。
Oncol Lett. 2023 Jul 5;26(2):359. doi: 10.3892/ol.2023.13945. eCollection 2023 Aug.
本文引用的文献
1
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.HER2 在癌症治疗中的分子途径和机制。
Clin Cancer Res. 2023 Jul 5;29(13):2351-2361. doi: 10.1158/1078-0432.CCR-22-0283.
2
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.一种编码 ERBB2 细胞内结构域的质粒 DNA 疫苗在晚期 ERBB2 阳性乳腺癌患者中的安全性和疗效：一项 1 期非随机临床试验。
JAMA Oncol. 2023 Jan 1;9(1):71-78. doi: 10.1001/jamaoncol.2022.5143.
3
Adenoviral-based vaccine promotes neoantigen-specific CD8 T cell stemness and tumor rejection.腺病毒载体疫苗促进了新抗原特异性 CD8 T 细胞干性和肿瘤排斥。
Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604.
4
Cancer vaccine strategies using self-replicating RNA viral platforms.基于自我复制 RNA 病毒平台的癌症疫苗策略。
Cancer Gene Ther. 2023 Jun;30(6):794-802. doi: 10.1038/s41417-022-00499-6. Epub 2022 Jul 12.
5
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.阿替利珠单抗联合新辅助抗人表皮生长因子受体 2 治疗与化疗用于人表皮生长因子受体 2 阳性早期乳腺癌：随机 III 期 IMpassion050 试验的主要结果。
J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28.
6
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南：乳腺癌》第 3.2022 版
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
7
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.实体瘤中抗体药物偶联物与免疫疗法的联合应用：现状与未来展望
Cancer Treat Rev. 2022 May;106:102395. doi: 10.1016/j.ctrv.2022.102395. Epub 2022 Apr 18.
8
Role of immunotherapy in metastatic EGFRm NSCLC: Is it relevant?免疫疗法在 EGFRm 转移性 NSCLC 中的作用：是否相关？
Indian J Cancer. 2022 Mar;59(Supplement):S68-S79. doi: 10.4103/ijc.IJC_49_21.
9
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
10
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.三特异性抗体靶向 HER2 和 T 细胞通过 CD4 细胞抑制乳腺癌生长。
Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23.
Zotero 插件